Bal Pharma Limited (BOM:524824)

India flag India · Delayed Price · Currency is INR
71.86
+2.06 (2.95%)
At close: Mar 10, 2026
-16.34%
Market Cap 1.14B
Revenue (ttm) 3.09B
Net Income (ttm) 81.23M
Shares Out 15.92M
EPS (ttm) 4.82
PE Ratio 14.91
Forward PE n/a
Dividend 1.20 (1.72%)
Ex-Dividend Date Sep 18, 2025
Volume 656
Average Volume 980
Open 70.80
Previous Close 69.80
Day's Range 67.15 - 72.00
52-Week Range 64.00 - 128.86
Beta 0.17
RSI 40.45
Earnings Date Feb 11, 2026

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p... [Read more]

Industry Pharmaceutical Preparations
Founded 1987
Employees 986
Stock Exchange Bombay Stock Exchange
Ticker Symbol 524824
Full Company Profile

Financial Performance

In fiscal year 2025, Bal Pharma's revenue was 3.03 billion, a decrease of -10.65% compared to the previous year's 3.39 billion. Earnings were 72.15 million, a decrease of -2.39%.

Financial Statements

News

There is no news available yet.